The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.
 
Nicole Maria Kuderer
Stock and Other Ownership Interests - Generex Biotechnology (I)
Consulting or Advisory Role - Agendia; Bayer; BeyondSpring Pharmaceuticals; Celldex; G1 Therapeutics (I); Genomic Health (I); Janssen; Mylan; Pfizer; Spectrum Pharmaceuticals
Research Funding - Amgen (I); Hexal (I)
Travel, Accommodations, Expenses - Agendia; Bayer; Janssen; Mylan; Spectrum Pharmaceuticals
 
Della Varghese
Employment - Pharmerit
Research Funding - Celldex
 
Kala Hill
Employment - Celldex
 
Gary H. Lyman
Stock and Other Ownership Interests - Generex Biotechnology
Consulting or Advisory Role - Agendia; Amgen; Celldex (I); G1 Therapeutics; Genomic Health; Halozyme; Helsinn Therapeutics; Janssen (I); Mylan; Partners Healthcare; Pfizer; Samsung Bioepis; Spectrum Pharmaceuticals
Research Funding - Hexal
 
Marc Botteman
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Helsinn Therapeutics (Inst); Kite/Gilead (Inst)
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Helsinn Therapeutics (Inst); Kite/Gilead (Inst)
Other Relationship - Pharmerit